Tiziana Life Sciences (TLSA)

• Market cap: $167M
• 1 day: -4.38%
• 5 days: -9.03%
• 1 month: -5.76%
• 3 months: -23.84%
• 6 months: -26.82%
• Year to date: -18.13%
• 1 year: -4.38%
• 5 years: -55.74%
• 10 years: -21.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Employees: 9